Docci D, Cipolloni P A, Mengozzi S, Baldrati L, Capponcini C, Feletti C
Servizio di Nefrologia e Dialisi, Ospedale M. Bufalini, Cesena, Italia.
Nephron. 1992;61(3):352-3. doi: 10.1159/000186939.
The immunogenicity of a recombinant hepatitis B vaccine was evaluated in 35 hemodialysis patients who received a standard dose (20 micrograms) of the vaccine at 0, 1, 2 and 6 months. After the full vaccination course (month 7), 60% (21/35) of the patients had seroconverted (anti-HBs titer greater than or equal to 10 mIU/ml). The duration of protection lasted up to 18 months after the start of vaccination in 85.7% (18/21) of the responders. At that time, an additional dose was given to all the patients: 1-2 months later, the overall immunization rate had increased to 65.7% (23/35); lastly, in month 24 (i.e., 6 months after the booster dose), 62.5% (15/24) of the patients available for evaluation were still maintaining protective levels of anti-HBs antibodies. Comparable results had previously been obtained in 21 well-matched patients on our dialysis program who were vaccinated with a plasma-derived vaccine according to the recommended schedule.
在35例血液透析患者中评估了重组乙型肝炎疫苗的免疫原性，这些患者在0、1、2和6个月时接受了标准剂量（20微克）的疫苗。在完成全程疫苗接种（第7个月）后，60%（21/35）的患者发生了血清转化（抗-HBs滴度大于或等于10 mIU/ml）。在85.7%（18/21）的应答者中，疫苗接种开始后保护期持续长达18个月。此时，给所有患者额外接种一剂疫苗：1至2个月后，总体免疫率升至65.7%（23/35）；最后，在第24个月（即加强剂量接种后6个月），可进行评估的患者中有62.5%（15/24）仍维持抗-HBs抗体的保护水平。此前，在我们透析项目中21例匹配良好的患者中，按照推荐方案接种血浆源性疫苗时也获得了类似结果。
